Given the commonly observed dysregulation of PI3K/Akt/mTOR pathway in T-ALL, the various types of single or dual pathway inhibitors under development might be effective in T-ALL treatment, provided that they do not affect the immune system. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.